Status:
UNKNOWN
Correlative Cohort Study on the Clinical Features and Prognosis of Drug-induced Liver Injury
Lead Sponsor:
Beijing Ditan Hospital
Conditions:
Drug-induced Liver Injury
Eligibility:
All Genders
18-75 years
Brief Summary
This was a retrospective study of a clinical observational cohort. The patients were admitted and definitely diagnosed by liver biopsy as drug-induced liver injury from September 2014 to September 201...
Detailed Description
This was a retrospective study of a clinical observational cohort. The patients were admitted and definitely diagnosed by liver biopsy as drug-induced liver injury from September 2014 to September 201...
Eligibility Criteria
Inclusion
- Have a clear history of taking drugs (Chinese herbal medicine and dietary supplements, NSAIDs, cardio-cerebrovascular drugs, anti-interference drugs, anti-tuberculosis drugs, hormone drugs and others);
- All patients were examined by liver biopsy Patients with clear diagnosis of drug-induced liver injury and clinical diagnosis of DILI who meet the RUCAM score.
Exclusion
- Combined with various liver diseases, such as viral hepatitis (hepatitis A, B, C, D, E), alcoholic hepatitis, autoimmune hepatitis, metabolic hepatitis, non-alcoholic fatty liver disease;
- Combining other viral infections that may lose liver function, such as Epstein-Barr Virus (EBV), Cytomegalovirus (CMV), and Human Immunodeficiency Virus (HIV);
- Mental illness;
- Evidence of liver tumors (liver cancer or alpha-fetoprotein\> 100 ng / ml).
Key Trial Info
Start Date :
April 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 30 2021
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT04302506
Start Date
April 1 2020
End Date
April 30 2021
Last Update
March 10 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Hepatology Division 2, Beijing Ditan Hospital
Beijing, Beijing Municipality, China, 100015